Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

2022171 citationsJournal Articlegold Open Access

Authors

Ming Yi · Tongji Hospital

Mengke Niu · Tongji Hospital

Yuze Wu · Tongji Hospital

Hong Ge · Zhengzhou University

Dechao Jiao · First Affiliated Hospital of Zhengzhou University

Shuangli Zhu · Tongji Hospital

Jing Zhang · Wuhan YZY Biopharma (China)

Abstract

Our results demonstrate that MSA-2 synergizes with YM101 in boosting antitumor immunity. This immune cocktail therapy effectively overcomes immunotherapy resistance in immune-excluded and immune-desert models.

Topics & Keywords

interferon and immune responses Cancer Immunotherapy and Biomarkers Ubiquitin and proteasome pathways

UN Sustainable Development Goals

Life in Land

Publication Details

Published in: Journal of Hematology & Oncology

Volume 15, Issue 1, pp. 142-142

DOI: 10.1186/s13045-022-01363-8

Field-Weighted Citation Impact: 14.79